This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Allison L. Holm, MD; Kathryn E. Bowers, MD; Thomas O. McMeekin, MD; Anthony A. Gaspari, MD

Arch Dermatol. 1993;129(12):1548-1550.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

REPORT OF A CASE

A 38-year-old woman presented with extensive scarring alopecia diagnosed as chronic cutaneous lupus erythematosus (CCLE) at age 21 years. A skin biopsy specimen confirmed the diagnosis, and repeated studies failed to reveal anti-nDNA (double-stranded or native), anti-Ro (SSA), or anti-La (SS-B) antibodies. She denied photosensitivity, arthralgias, pericarditis, pleurisy, renal or hematologic disease, or psychiatric disorders.

Half of the scalp was involved, with an extensive atrophic scarring alopecia that demonstrated patchy hyperpigmentation, hypopigmentation, and erythema (Figure 1). Scattered follicular plugs were also present.

The patient received quinacrine (Atabrine) (100 mg twice daily) from October 1983 through May 1987. In October 1985, hydroxychloroquine (Plaquenil Sulfate) was added to therapy, with the dose increasing from 200 to 400 mg/d. Hydroxychloroquine therapy was discontinued in April 1989, and dapsone (50 mg/d) was substituted in June 1989 for 8 weeks. Isotretinoin (Accutane) . . . [Full Text PDF of this Article]

Author Affiliations
University of Rochester (NY) Medical Center

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?